One trial of IL-6 inhibitors found improved survival among patients on organ support, while another found no difference in rates of recovery with tocilizumab versus placebo. An online calculator offered a new score for predicting progression of COVID-19, and a study categorized patients into three phenotypes.
The Johnson & Johnson COVID-19 vaccine got an emergency use authorization, and an Israeli study provided more data on the Pfizer vaccine. The NIH named long-term symptoms as post-acute sequelae of SARS-CoV-2 (PASC).
The VICTAS Trial found no increase in ventilator- or vasopressor-free days within 30 days in critically ill patients with sepsis who received vitamin C, thiamine, and hydrocortisone versus placebo.
While one study found that participation in an antibiotic stewardship program from the Agency for Healthcare Research and Quality led to reductions in hospital-onset Clostridioides difficile infection rates, a simulation study found that visitor contact precautions may not be as helpful.
The AREST trial, which ended early due to changes in national guidelines, found statistically similar but numerically lower rates of the primary study outcome (fatal stroke, recurrent ischemic stroke, or transient ischemic attack) in those who received anticoagulation early with apixaban versus later with warfarin.